# Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

> **NCT02596555** · PHASE4 · TERMINATED · sponsor: **Prof. Stavros Konstantinides, MD** · enrollment: 400 (actual)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Dabigatran

## Key facts

- **NCT ID:** NCT02596555
- **Lead sponsor:** Prof. Stavros Konstantinides, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 400 (ACTUAL)
- **Why stopped:** 1. Interim results suggested a reduction of sample size.
2. Anticipated length of enrolment period with resulting funding issues to pose a threat to the study.
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596555, "Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02596555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*